Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.

Lee SC, North K, Kim E, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, Yeo M, Zhang XJ, Kim MK, Cho H, Chung YR, Taylor J, Durham BH, Kim YJ, Pastore A, Monette S, Palacino J, Seiler M, Buonamici S, Smith PG, Ebert BL, Bradley RK, Abdel-Wahab O.

Cancer Cell. 2018 Aug 13;34(2):225-241.e8. doi: 10.1016/j.ccell.2018.07.003.

PMID:
30107174
2.

Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens.

Hoyos LE, Abdel-Wahab O.

Cancer Cell. 2018 Aug 13;34(2):181-183. doi: 10.1016/j.ccell.2018.07.008.

PMID:
30107172
3.

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R.

Hematol Oncol. 2018 Aug 3. doi: 10.1002/hon.2537. [Epub ahead of print] Review.

PMID:
30074634
4.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2018 Jul 23. doi: 10.1038/s41375-018-0215-9. [Epub ahead of print]

PMID:
30038380
5.

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O.

J Clin Invest. 2018 Aug 6. pii: 120787. doi: 10.1172/JCI120787. [Epub ahead of print]

6.

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.

Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, Chung YR, Hendrickson R, Hsieh J, Berger M, Schultz N, Pastore A, Abdel-Wahab O, Chandarlapaty S.

Oncogene. 2018 May 14. doi: 10.1038/s41388-018-0273-5. [Epub ahead of print]

PMID:
29755131
7.

Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.

Chang CJ, Kotini AG, Olszewska M, Georgomanoli M, Teruya-Feldstein J, Sperber H, Sanchez R, DeVita R, Martins TJ, Abdel-Wahab O, Bradley RK, Papapetrou EP.

Stem Cell Reports. 2018 May 8;10(5):1610-1624. doi: 10.1016/j.stemcr.2018.03.020. Epub 2018 Apr 19.

8.

Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.

Nagase R, Inoue D, Pastore A, Fujino T, Hou HA, Yamasaki N, Goyama S, Saika M, Kanai A, Sera Y, Horikawa S, Ota Y, Asada S, Hayashi Y, Kawabata KC, Takeda R, Tien HF, Honda H, Abdel-Wahab O, Kitamura T.

J Exp Med. 2018 Jun 4;215(6):1729-1747. doi: 10.1084/jem.20171151. Epub 2018 Apr 11.

PMID:
29643185
9.

Editorial overview: Cancer genomics: RNA metabolism and translation in cancer pathogenesis and therapy.

Abdel-Wahab O, Gebauer F.

Curr Opin Genet Dev. 2018 Feb;48:iv-vi. doi: 10.1016/j.gde.2018.01.007. No abstract available.

PMID:
29576046
10.

SETD2 - linking stem cell survival and transformation.

Patnaik MM, Abdel-Wahab O.

Cell Res. 2018 Apr;28(4):393-394. doi: 10.1038/s41422-018-0025-7. No abstract available.

PMID:
29572486
11.

The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, Wang M, Kang HB, Pan Y, Liu S, Chung YR, Abdel-Wahab O, Merghoub T, Rossi M, Kudchadkar RR, Lawson DH, Khuri FR, Lonial S, Chen J.

Mol Cell. 2018 Mar 15;69(6):923-937.e8. doi: 10.1016/j.molcel.2018.02.010.

PMID:
29547721
12.

Targeting mRNA Decapping in AML.

Yoshimi A, Abdel-Wahab O.

Cancer Cell. 2018 Mar 12;33(3):339-341. doi: 10.1016/j.ccell.2018.02.015.

PMID:
29533777
13.

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N.

Cancer Discov. 2018 May;8(5):648-661. doi: 10.1158/2159-8290.CD-17-1452. Epub 2018 Feb 26.

PMID:
29483135
14.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

15.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

PMID:
29466766
16.

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.

Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S.

Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19.

PMID:
29457796
17.

The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.

Chen L, Chen JY, Huang YJ, Gu Y, Qiu J, Qian H, Shao C, Zhang X, Hu J, Li H, He S, Zhou Y, Abdel-Wahab O, Zhang DE, Fu XD.

Mol Cell. 2018 Feb 1;69(3):412-425.e6. doi: 10.1016/j.molcel.2017.12.029. Epub 2018 Jan 27.

18.

The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.

Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR, Busam KJ, Travis WD, Diamond EL, Dogan A.

Mod Pathol. 2018 Apr;31(4):581-597. doi: 10.1038/modpathol.2017.160. Epub 2017 Dec 1.

PMID:
29192649
19.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.

PMID:
29188284
20.

Therapeutic targeting of RNA splicing in myelodysplasia.

Kim YJ, Abdel-Wahab O.

Semin Hematol. 2017 Jul;54(3):167-173. doi: 10.1053/j.seminhematol.2017.06.007. Epub 2017 Jul 12. Review.

PMID:
28958291
21.

A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease.

Mass E, Jacome-Galarza CE, Blank T, Lazarov T, Durham BH, Ozkaya N, Pastore A, Schwabenland M, Chung YR, Rosenblum MK, Prinz M, Abdel-Wahab O, Geissmann F.

Nature. 2017 Sep 21;549(7672):389-393. doi: 10.1038/nature23672. Epub 2017 Aug 30.

22.

Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.

Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, Ng V, Xia B, Witkowski MT, Mitchell-Flack M, Grillo I, Bakogianni S, Ndiaye-Lobry D, Martín MT, Guillamot M, Banh RS, Xu M, Figueroa ME, Dickins RA, Abdel-Wahab O, Park CY, Tsirigos A, Neel BG, Aifantis I.

Cell. 2017 Sep 7;170(6):1079-1095.e20. doi: 10.1016/j.cell.2017.07.032. Epub 2017 Aug 17.

23.

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.

Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hüllein J, Walther T, Wang L, Lu SX, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O.

Blood. 2017 Oct 5;130(14):1644-1648. doi: 10.1182/blood-2017-01-765107. Epub 2017 Aug 11.

24.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

PMID:
28748614
25.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

PMID:
28679734
26.

Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms.

Ozkaya N, Dogan A, Abdel-Wahab O.

Hematol Oncol Clin North Am. 2017 Aug;31(4):705-719. doi: 10.1016/j.hoc.2017.04.008. Epub 2017 May 17. Review. Erratum in: Hematol Oncol Clin North Am. 2018 Apr;32(2):xiii.

27.

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A.

Leukemia. 2018 Feb;32(2):413-418. doi: 10.1038/leu.2017.186. Epub 2017 Jun 13.

28.

Diagnosis and classification of hematologic malignancies on the basis of genetics.

Taylor J, Xiao W, Abdel-Wahab O.

Blood. 2017 Jul 27;130(4):410-423. doi: 10.1182/blood-2017-02-734541. Epub 2017 Jun 9. Review.

29.

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O.

Blood. 2017 Jul 27;130(4):397-407. doi: 10.1182/blood-2017-01-763219. Epub 2017 Jun 2. Erratum in: Blood. 2017 Sep 28;130(13):1602.

30.

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.

Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, Hélias-Rodzewicz Z, Terrones N, Ozkaya N, Dogan A, Rampal R, Urbain F, Le Fèvre L, Diamond EL, Park CY, Papo T, Charlotte F, Gorochov G, Taly V, Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF.

Blood. 2017 Jul 13;130(2):176-180. doi: 10.1182/blood-2016-12-757377. Epub 2017 May 31.

31.

The clinical spectrum of Erdheim-Chester disease: an observational cohort study.

Estrada-Veras JI, O'Brien KJ, Boyd LC, Dave RH, Durham B, Xi L, Malayeri AA, Chen MY, Gardner PJ, Alvarado-Enriquez JR, Shah N, Abdel-Wahab O, Gochuico BR, Raffeld M, Jaffe ES, Gahl WA.

Blood Adv. 2017 Feb 14;1(6):357-366. doi: 10.1182/bloodadvances.2016001784.

32.

Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.

Jin S, Su H, Tran NT, Song J, Lu SS, Li Y, Huang S, Abdel-Wahab O, Liu Y, Zhao X.

PLoS One. 2017 May 18;12(5):e0175523. doi: 10.1371/journal.pone.0175523. eCollection 2017.

33.

ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.

Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O.

Nat Commun. 2017 May 18;8:15429. doi: 10.1038/ncomms15429.

34.

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.

Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M.

Blood. 2017 Jul 13;130(2):167-175. doi: 10.1182/blood-2016-12-757823. Epub 2017 May 16.

35.

HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.

Zhao L, Fan J, Xia S, Pan Y, Liu S, Qian G, Qian Z, Kang HB, Arbiser JL, Pollack BP, Kudchadkar RR, Lawson DH, Rossi M, Abdel-Wahab O, Merghoub T, Khoury HJ, Khuri FR, Boise LH, Lonial S, Chen F, Chen J, Lin R.

J Biol Chem. 2017 Jun 16;292(24):10142-10152. doi: 10.1074/jbc.M117.788778. Epub 2017 May 3.

36.

Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.

Yoshimi A, Abdel-Wahab O.

Int J Hematol. 2017 Jun;105(6):720-731. doi: 10.1007/s12185-017-2242-0. Epub 2017 May 2. Review.

PMID:
28466384
37.

Modeling CBL activating mutations in vivo.

Lee SC, Abdel-Wahab O.

Blood. 2017 Apr 13;129(15):2046-2048. doi: 10.1182/blood-2017-03-770222. No abstract available.

38.

How do messenger RNA splicing alterations drive myelodysplasia?

Joshi P, Halene S, Abdel-Wahab O.

Blood. 2017 May 4;129(18):2465-2470. doi: 10.1182/blood-2017-02-692715. Epub 2017 Mar 27. Review.

39.

Partial loss of genes might open therapeutic window.

Liu B, Abdel-Wahab O.

Elife. 2017 Mar 17;6. pii: e25996. doi: 10.7554/eLife.25996.

40.

Histiocytoses: emerging neoplasia behind inflammation.

Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, Vaglio A, Abdel-Wahab O, Emile JF, Amoura Z.

Lancet Oncol. 2017 Feb;18(2):e113-e125. doi: 10.1016/S1470-2045(17)30031-1. Review.

PMID:
28214412
41.

Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, Chen J.

Cell Metab. 2017 Feb 7;25(2):358-373. doi: 10.1016/j.cmet.2016.12.010. Epub 2017 Jan 12.

42.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

43.

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.

Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB.

Oncotarget. 2016 Dec 20;7(51):85430-85436. doi: 10.18632/oncotarget.13397.

44.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

45.

Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.

Yoshimi A, Abdel-Wahab O.

Clin Cancer Res. 2017 Jan 15;23(2):336-341. doi: 10.1158/1078-0432.CCR-16-0131. Epub 2016 Nov 10.

46.

Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia.

Getta BM, Woo KM, Devlin S, Park JH, Abdel-Wahab O, Saven A, Rai K, Tallman MS.

Br J Haematol. 2016 Nov;175(3):402-409. doi: 10.1111/bjh.14207. Epub 2016 Jun 28.

47.

Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.

Lu SX, Abdel-Wahab O.

Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11071-11073. Epub 2016 Sep 23. No abstract available.

48.

Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities.

Inoue D, Abdel-Wahab O.

Cancer Cell. 2016 Sep 12;30(3):371-373. doi: 10.1016/j.ccell.2016.08.013.

49.

Therapeutic targeting of splicing in cancer.

Lee SC, Abdel-Wahab O.

Nat Med. 2016 Sep 7;22(9):976-86. doi: 10.1038/nm.4165. Review.

50.

Defining risk in MDS over time.

Yoshimi A, Abdel-Wahab O.

Blood. 2016 Aug 18;128(7):885-6. doi: 10.1182/blood-2016-07-724930. No abstract available.

Supplemental Content

Loading ...
Support Center